AT 13148
Alternative Names: AT-13148Latest Information Update: 05 Nov 2023
At a glance
- Originator Astex Therapeutics; Cancer Research UK; The Institute of Cancer Research
- Developer Astex Pharmaceuticals; Cancer Research UK
- Class Antineoplastics; Benzamides; Piperidines; Small molecules
- Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto-oncogene protein c-akt inhibitors; Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (PO)
- 15 Sep 2020 AT 13148 is still in phase I trials for Solid tumours in United Kingdom (PO) (Cancer research UK pipeline, September 2020)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (PO)